winner
- Atlis Motor Vehicles Inc AMV Soared 211.7% to $256.00 in premarket trading after rising 199% on Tuesday.
- Silo Pharma, Inc. SILO Soared 105% to $10.46 in premarket trading after being uplisted on the Nasdaq.
- Biogen Inc. BIIB Shares are up 39.7% in premarket trading to $276.32. Biogen and Eisai Co. late Tuesday announced positive results from a late-stage study of their Alzheimer’s treatment candidate.
- Prothena Corporation plc PRTA up 37.4% to $42.50 in premarket trading in sympathy with Biogen.
- Acumen Pharmaceuticals, Inc. SUBSCRIPTION Soared 29.8% to $6.10 in premarket trading after gaining around 6% on Tuesday.
- Flora Growth Corp. FLGC Soared 17.9% to $0.8621 in premarket trading after falling 8% on Tuesday.
- MorphoSys AG MOR rose 17.7% to $5.24 in premarket trading.
- Longeveron Inc. LGVN rose 16.9% to $4.71 in premarket trading. Longeveron last month received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of hypoplastic left heart syndrome (HLHS).
- AIM ImmunoTech Inc. TARGET Soared 16.4% to $0.6750 in premarket trading after falling around 7% on Tuesday.
- ASAP, Inc. WTRH Soared 12.1% to $0.1793 in premarket trading after falling around 9% on Tuesday.
- Windtree Therapeutics, Inc. WINT rose 12% to $0.35 in premarket trading.
- BioVie Inc. BIVI rose 11.8% to $2.64 in premarket trading. BioVie recently announced top-line results from an investigator-sponsored Phase 2 clinical trial of NE3107 in the treatment of Alzheimer’s disease, stating that “the vast majority of patients have experienced significant improvements in the Global Rating of Change.”
- Locafy Limited LCFY Soared 10.5% to $0.42 in premarket trading after falling about 6% on Tuesday.
- Cassava Sciences, Inc. SAVA rose 10.2% to $50.90 in premarket trading. Shares of companies with potential Alzheimer’s treatments are trading higher premarket in sympathy with Biogen.
- Quanterix Corporation QTRX up 9.2% premarket to $8.80…
